Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | IAPP | P10997 | 1/20 | 0.55 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31464870 | 1.00 | MAPT (0.63) | MAPTLMNANFE2L2KDM4EMAOB | |
| SCHEMBL1781200 | 1.00 | MAPT (0.63) | MAPTLMNANFE2L2KDM4EMAOB | |
| SCHEMBL29374751 | 1.00 | MAPT (0.63) | MAPTLMNANFE2L2KDM4EMAOB | |
| SCHEMBL14441077 | 0.85 | MAPT (0.76) | MAPTLMNANFE2L2KDM4ERAB9A | |
| SCHEMBL3581314 | 0.83 | NFE2L2 (0.62) | MAPTLMNANFE2L2MAOBRAB9A | |
| SCHEMBL3581316 | 0.83 | NFE2L2 (0.62) | MAPTLMNANFE2L2MAOBRAB9A | |
| SCHEMBL29365442 | 0.82 | CA1 (0.62) | MAPTNFE2L2MAOBRAB9ASMN1; SMN2 | |
| SCHEMBL79638 | 0.82 | CA1 (0.62) | MAPTNFE2L2MAOBRAB9ASMN1; SMN2 | |
| SCHEMBL27829211 | 0.82 | NFE2L2 (0.60) | MAPTLMNANFE2L2MAOBRAB9A | |
| SCHEMBL79637 | 0.82 | CA1 (0.62) | MAPTNFE2L2MAOBRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8592430-B2 | Quinazolin-oxime derivatives as Hsp90 inhibitors | DAC SLR (IT) | 2013-11-26 | — | — | US | disclosed |
| EP-2144889-B1 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | DAC SRL (IT) | 2012-08-29 | — | — | EP | disclosed |
| US-20110118258-A1 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | DAC SRL (IT) | 2011-05-19 | — | — | US | disclosed |
| EP-2144889-A2 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | DAC S.r.l. (IT) | 2010-01-20 | — | — | EP | disclosed |
| WO-2008142720-A2 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | DAC SRL (IT) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118258-A1 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | HSP90AB1, HSP90AA1, HSP90B1 | MAPT 296/4885LMNA 4565/4885NFE2L2 550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.